ClinicalTrials.gg
RecruitingNCT07549412Updated Nov 5, 2026

A Study of Precemtabart Tocentecan With or Without Bevacizumab Compared to Trifluridine/Tipiracil Plus Bevacizumab in Participants With Previously Treated Metastatic Colorectal Cancer (PROCEADE-CRC-03)

A Phase 3 interventional study of Precemtabart tocentecan and Bevacizumab in Metastatic Colorectal Cancer, sponsored by EMD Serono Research & Development Institute, Inc.. Recruiting at 116 sites in 19 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-05.

Sponsored by EMD Serono Research & Development Institute, Inc. (part of Merck KGaA, Darmstadt, Germany) · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started May 2026; still recruiting 6 months later.
Updated Nov 5, 2026First sites in Italy, Netherlands and Denmark50 sites addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,020
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 230 studies testing bevacizumab in Colorectal Neoplasms — 49 open to participants now, 61 under way, 11 of them phase 3. Bevacizumab · Colorectal Neoplasms.

Planned enrollment
5th of 224
1,020 · median 63
Started
2026
with 12 others
Phase 3
42 of 230
4 open now
Primary completion
2029-10
later than 56 of 60 live
Registered
227th of 230
by date

Among the 230 studies testing bevacizumab in Colorectal Neoplasms, this one is the 5th largest by planned enrollment of the 224 interventional ones that give a count, is one of 13 that started in 2026, is one of 42 in phase 3, reaches primary completion later than 56 of the 60 other live ones, and was the 227th registered.

Colorectal Neoplasms

6,548 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

49 of the 230 studies testing bevacizumab in Colorectal Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

43 more — sign in →

By country, each count listing its studies:

All 49 open studies →

About bevacizumab

Bevacizumab: first FDA approval 2004 (AVASTIN), first EMA approval 2005. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 230 studies testing bevacizumab in Colorectal Neoplasms, or all of them as a file.
02

Study summary

This study aims to address the unmet medical need of participants with metastatic colorectal cancer (mCRC) who have previously been treated with irinotecan, oxaliplatin, a fluoropyrimidine, and bevacizumab, by demonstrating an overall survival prolongation with precemtabart tocentecan (Precem-TcT) as single agent or Precem-TcT in combination with bevacizumab compared to trifluridine/tipiracil (FTD-TPI) plus bevacizumab.

03

Conditions studied

  • Metastatic Colorectal Cancer

Keywords

  • CEACAM5
  • Antibody-drug conjugate
  • Exatecan
  • M9140
  • Precem-TcT
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants with documented histopathological diagnosis of colorectal cancer, who were intolerant to, or whose disease was to, or progressed after standard systemic therapies and no more than 2 previous systemic treatment regimens in the metastatic setting.
  • Participants must have received and progressed on no more than 2 previous systemic treatment regimens in the metastatic setting
  • (ECOG) performance status less than equal to 1
  • Participants must be able to swallow oral tablets, and to comply with the study requirements for all scheduled evaluations
  • Other protocol defined inclusion criteria may apply

Exclusion criteria

Exclusion Criteria:

  • If Adverse Events related to previous therapies have not recovered to less than Grade 1 by National Cancer Institute - version 6.0
  • Participant has a history of additional within 3 years before randomization
  • Participants with known
  • Abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within the past 6 months prior to randomization
  • Participants with ileus of more than Grade 1, or chronic inflammatory bowel disease (example ulcerative colitis, Crohn's disease) and/or bowel obstruction, or participants with chronic gastrointestinal disorders that, in the Investigator's opinion, might significantly interfere with proper absorption of the study treatments
  • Other protocol defined exclusion criteria may apply
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1,020 participants (estimated)

Study arms

  • Experimental
    Arm 1: Precemtabart tocentecan (Precem-TcT) Monotherapy

    Drug: Precemtabart tocentecan

  • Experimental
    Arm 2: Precem-TcT plus Bevacizumab

    Drug: Precemtabart tocentecan · Drug: Bevacizumab

  • Active comparator
    Arm 3: Trifluridine/Tipiracil (FTD-TPI) plus Bevacizumab

    Drug: Bevacizumab · Drug: Trifluridine/Tipiracil (FTD-TPI)

Interventions

  • Precem-TcT, administered, once every 3 weeks intravenously, on Day 1 of each 21-day cycle.

    Also known as: Precem-TcT

  • Bevacizumab, administered intravenously every 3 weeks on Day 1 of each 21-day cycle or every 2 weeks on Day 1 and Day 15 of each 28-day cycle.

  • DrugTrifluridine/Tipiracil (FTD-TPI)

    FTD-TPI, tablet, administered orally twice daily, on Days 1 to 5 and Days 8 to 12 of each 28-day cycle.

06

What researchers measure

Primary outcomes

  1. Arm 1, 2 and 3: Overall Survival

    Time frame: Time from date of randomization to death, assessed approximately up to average of 19 months

Secondary outcomes

  1. Arm 1 and Arm 2: Overall Survival

    Time frame: Time from date of randomization to death, assessed approximately up to average of 19 months

  2. Progression Free Survival (PFS)

    Time frame: Time from randomization to the first occurrence of disease progression or death, whichever occurs first (assessed up to average of 19 months)

  3. Objective Response (OR) According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) as Assessed by Investigator

    Time frame: Up to average of 19 months

  4. Duration of Response as Assessed by Investigator

    Time frame: Time from first documentation of objective response to PD or death (assessed up to average of 19 months)

  5. Number of Participants with Adverse Events (AEs) and Treatment Related Adverse Events

    Time frame: Up to average of 19 months

  6. Observed Concentration at End of Infusion (CEOI) Period

    Time frame: At end of infusion on Cycle 1 Day 1 and Cycle 3 Day 1 (Arm 1 and Arm 2 only; each cycle is for 21 days)

  7. Concentration Observed at the end of a Dosing Interval Immediately Before next Dosing (Ctrough)

    Time frame: At end of dosing interval on Cycle1Day1,Cycle2Day1,Cycle3Day1,Cycle4Day1, Cycle5Day1,Cycle6Day1,Cycle7Day1 until treatment discontinuation(assessed up to average of 19months (Arm 1 and Arm 2 only; each cycle is for 21 days)

  8. Number of Participants with Anti-Drug Antibody as measured by ADA assay

    Time frame: Predose(-4to0 hours)on Cycle1Day1,Cycle2 Day1,Cycle 3Day1,Cycle4Day1, Cycle8Day1;thereafter every 4cycles until treatment discontinuation(assessed up to average of 19 months) (Arm 1 and Arm 2 only; each cycle is for 21 days)

  9. Change from Baseline in Global Health Status, Physical, and Role Functioning Subscale Scores of European Organization for research and Treatment of Cancer Quality of Life Core Questionnaire (EORTC QLQ-C30)

    EORTC QLQ-C30 is a 30-question tool used to assess the overall quality of life (QoL) in cancer participants. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, role, cognitive, emotional, social), and 9 symptom scales/items (Fatigue, nausea and vomiting, pain, dyspnea, sleep disturbance, appetite loss, constipation, diarrhea, financial impact. The EORTC QLQ-C30 GHS/QoL score ranges from 0 to 100; High score indicates better GHS/QoL. Score 0 represents: very poor physical condition and QoL. Score 100 represents: excellent overall physical condition and QoL.

    Time frame: Baseline, Cycle 1 Day 1 and Day 1 of every new cycle until treatment discontinuation (assessed up to average of 19 months).

07

Study locations

116 of 116 sites recruiting
  • UCSF Mount Zion Medical Ctr
    San Francisco, California 94158, United States
    Recruiting
  • Rocky Mountain Cancer Centers, LLP- Aurora
    Lone Tree, Colorado 80124, United States
    Recruiting
  • Florida Cancer Specialists-Broadway
    Fort Myers, Florida 33901, United States
    Recruiting
  • Florida Cancer Specialists - St. Petersburg Bayfront
    St. Petersburg, Florida 33701-4553, United States
    Recruiting
  • Florida Cancer Specialists East - FCS EAST - West Palm Beach
    West Palm Beach, Florida 33401, United States
    Recruiting
  • Illinois Cancer Specialists
    Arlington Heights, Illinois 60005, United States
    Recruiting
  • Illinois CancerCare PC
    Peoria, Illinois 61615-7822, United States
    Recruiting
  • Springfield Clinic
    Springfield, Illinois 62702, United States
    Recruiting
  • Profound Research LLC at Cancer and Leukemia Center
    Sterling Heights, Michigan 48098, United States
    Recruiting
  • Minnesota Oncology Hematology, P.A.
    Saint Louis Park, Minnesota 55416, United States
    Recruiting
  • Missouri Cancer Associates - 150518964
    Columbia, Missouri 65201, United States
    Recruiting
  • White Plains Hospital Medical and Wellness PRIME
    White Plains, New York 10601, United States
    Recruiting
  • Prisma Health Cancer Institute, ITOR, CRU
    Greenville, South Carolina 29605, United States
    Recruiting
  • Avera Cancer Institute - 300127370
    Sioux Falls, South Dakota 57105, United States
    Recruiting
  • SCRI Oncology Partners
    Nashville, Tennessee 37203, United States
    Recruiting
  • Texas Oncology, P.A. - Abilene - 300210366
    Abilene, Texas 79606, United States
    Recruiting
  • Texas Oncology-South Austin
    Austin, Texas 78745, United States
    Recruiting
  • Texas Oncology DFW
    Bedford, Texas 75246, United States
    Recruiting
  • Texas Oncology- San Antonio
    San Antonio, Texas 78240, United States
    Recruiting
  • Texas Oncology, P.A. - Tyler
    Tyler, Texas 75702, United States
    Recruiting
  • Virginia Oncology Associates
    Newport News, Virginia 23606, United States
    Recruiting
  • Blue Ridge Cancer Care - 300202915
    Roanoke, Virginia 24014-2419, United States
    Recruiting
  • Instituto de Oncologia de Rosario
    Rosario, Santa Fe Province S2000KZE, Argentina
    Recruiting
  • Investigaciones Clinicas Moleculares ICM
    Ciudad Autonoma Buenos Aires, C1417DTB, Argentina
    Recruiting
  • Centro Oncologico de Excelencia
    San Juan, 5400, Argentina
    Recruiting
  • Centro de Investigaciones Medicas Tucuman
    San Miguel de Tucumán, T4000AXL, Argentina
    Recruiting
  • GenesisCare North Shore (Oncology)
    St Leonards, New South Wales 2065, Australia
    Recruiting
  • Icon Cancer Centre Chermside
    Chermside, Queensland 4032, Australia
    Recruiting
  • Mater Misericordiae Ltd - PARENT
    South Brisbane, Queensland 4101, Australia
    Recruiting
  • Flinders Medical Centre
    Bedford Park, South Australia 5042, Australia
    Recruiting
  • LKH - Universitätsklinikum der PMU Salzburg - Innere Med III/Hämatologie und Onkologie
    Salzburg, 5020, Austria
    Recruiting
  • AKH - Medizinische Universität Wien - Klinik für Innere Medizin 1
    Vienna, 1090, Austria
    Recruiting
  • Cliniques Universitaires Saint-Luc - STL
    Brussels, 1200, Belgium
    Recruiting
  • Grand Hospital de Charleroi - PARENT
    Charleroi, 6000, Belgium
    Recruiting
  • UZA - Account 3
    Edegem, 2650, Belgium
    Recruiting
  • UZ Leuven
    Leuven, 03000, Belgium
    Recruiting
  • BC Cancer - Vancouver - BC Cancer Agency
    Vancouver, British Columbia V5Z 4E6, Canada
    Recruiting
  • The Ottawa Hospital Cancer Centre
    Ottawa, Ontario K1H 8L6, Canada
    Recruiting
  • University Health Network - Princess Margaret Cancer Centre
    Toronto, Ontario M5G 2M9, Canada
    Recruiting
  • Beijing Cancer Hospital
    Beijing, Beijing Municipality 100142, China
    Recruiting
  • Peking Union Medical College Hospital
    Beijing, Beijing Municipality 100142, China
    Recruiting
  • Sun Yat-sen University Cancer Center
    Guangzhou, Guangdong 510060, China
    Recruiting
  • The Sixth Affiliated Hospital of Sun Yat-sen University
    Guangzhou, Guangdong 510655, China
    Recruiting
  • Meizhou Peoples Hospital - 300164707
    Meizhou, Guangdong 514031, China
    Recruiting
  • Guangxi Medical University Cancer Hospital
    Nanning, Guangxi Zhuang 530021, China
    Recruiting
  • The University of Hong Kong - 1
    Hong Kong, Hong Kong 00000, China
    Recruiting
  • Union Hospital Tongji Medical College Huazhong University of Science and Technology
    Wuhan, Hubei 430060, China
    Recruiting
  • Jiangsu Province Hospital
    Nanjing, Jiangsu 210029, China
    Recruiting
  • The First Affiliated Hospital of Nanchang University - Endocrine Secretion Department
    Nanchang, Jiangxi 330006, China
    Recruiting
  • Fudan University Shanghai Cancer Center
    Shanghai, Shanghai Municipality 201321, China
    Recruiting
  • Sichuan Cancer Hospital
    Chengdu, Sichuan 610041, China
    Recruiting
  • West China Hospital, Sichuan University
    Chengdu, Sichuan 610041, China
    Recruiting
  • The Second Affiliated Hospital of Zhejiang University School of Medicine - 300173725
    Hangzhou, Zhejiang 310000, China
    Recruiting
  • The First Affiliated Hospital, College of Medicine, Zhejiang University
    Hangzhou, Zhejiang 310003, China
    Recruiting
  • Ålborg Universitets Hospital - PARENT
    Herning, 7400, Denmark
    Recruiting
  • Institut Paoli Calmettes - service d'oncologie medicale
    Marseille, Bouches-du-Rhône 13009, France
    Recruiting
  • Centre Francois Baclesse - Service d'Oncologie Medicale
    Caen, Calvados 14033, France
    Recruiting
  • Institut Bergonié - Service d'Oncologie Médicale
    Bordeaux, Gironde 33076, France
    Recruiting
  • Hopital Claude Huriez - CHU Lille - service d'oncologie medicale
    Lille, Nord 59037, France
    Recruiting
  • CHU Saint Etienne - Hôpital Nord - Service de Gastro-Entérologie et Hépatologie
    Saint Priest En Jarez, Pays de la Loire Region 42270, France
    Recruiting
  • Centre Leon Berard - Service d'Oncologie Medicale
    Lyon, Rhone 69008, France
    Recruiting
  • Institut Gustave Roussy - Pathologies Digestives
    Villejuif, Val De Marne 94805, France
    Recruiting
  • Groupe Hospitalier Pitie-Salpetriere - Service Hépato-Gastro-Entérologie
    Paris, 75013, France
    Recruiting
  • Hôpital Européen Georges Pompidou - Hématologie Oncologie
    Paris, 75015, France
    Recruiting
  • Krankenhaus Nordwest GmbH - Neurologische Klinik
    Frankfurt am Main, Hesse 60488, Germany
    Recruiting
  • Universitaetsklinikum Leipzig AoeR - Universitaeres Krebszentrum Leipzig (UCCL)
    Leipzig, Saxony 04103, Germany
    Recruiting
  • Charité - Campus Charité Mitte - Medizinische Klinik II (Onkologie u. Haematologie)
    Berlin, 13353, Germany
    Recruiting
  • Haematologisch-Onkologische Praxis Eppendorf (HOPE)
    Hamburg, 20249, Germany
    Recruiting
  • The Chinese University of Hong Kong (CUHK) - Prince of Wales Hospital (PWH)
    Hong Kong, 00000, Hong Kong
    Recruiting
  • Azienda Ospedaliera Saverio De Bellis - 300205674
    Castellana Grotte, Bari 70013, Italy
    Recruiting
  • IEO Istituto Europeo di Oncologia - Divisione Oncologia Medica
    San Giovanni Rotondo, Foggia 71013, Italy
    Recruiting
  • Azienda Socio Sanitaria Territoriale Niguarda (Grande Ospedale Metropolitano Niguarda) - Struttura Complessa di Oncologia Falck
    Milan, 20162, Italy
    Recruiting
  • Azienda Ospedaliera Universitaria- Università degli Studi della Campania "Luigi Vanvitelli" - Dipartimento di Oncologia
    Naples, 80131, Italy
    Recruiting
  • Istituto Nazionale Tumori Fondazione G. Pascale - Dipartimento Oncoematologia
    Naples, 80131, Italy
    Recruiting
  • IOV - Istituto Oncologico Veneto IRCCS - S.Semplice Dip.Oncologia dei Melanomi
    Padova, 35128, Italy
    Recruiting
  • Azienda Ospedaliero Universitaria Pisana - U.O. Oncologia II
    Pisa, 56126, Italy
    Recruiting
  • Fondazione Policlinico Universitario Agostino Gemelli IRCCS - UOC Oncologia Medica
    Rome, 00168, Italy
    Recruiting
  • Aichi Cancer Center Hospital
    Nagoya, Aichi-ken 464-8681, Japan
    Recruiting
  • NHO Kyushu Cancer Center - 300175822
    Fukuoka, Fukuoka 811-1395, Japan
    Recruiting
  • Kanagawa Cancer Center - Dept of Gastroenterology
    Yokohama, Kanagawa 241-8515, Japan
    Recruiting
  • Kindai University Hospital
    Sakai-shi, Osaka 590-0197, Japan
    Recruiting
  • Saitama Cancer Center - 300175812
    Kitaadachi-gun, Saitama 362-0806, Japan
    Recruiting
  • Shizuoka Cancer Center
    Sunto, Shizuoka 411-8777, Japan
    Recruiting
  • National Cancer Center Hospital
    Chūōku, Tokyo-To 104-0045, Japan
    Recruiting
  • Cancer Institute Hospital of JFCR
    Kōtoku, Tokyo-To 135-8550, Japan
    Recruiting
  • Osaka International Cancer Institute
    Osaka, 541-8567, Japan
    Recruiting
  • Universitair Medisch Centrum Groningen - Cancer Center
    Groningen, 9713GZ, Netherlands
    Recruiting
  • Amphia Ziekenhuis, Molengracht - Parent
    Utrecht, 3584 CX, Netherlands
    Recruiting
  • Wojewodzkie Centrum Onkologii
    Gdansk, 80-219, Poland
    Recruiting
  • SP ZOZ Szpital Uniwersytecki w Krakowie - Dept of Clinical Oncology and Oncology Clinic
    Krakow, 31-501, Poland
    Recruiting
  • National Cancer Center
    Goyang-si, Gyeonggi-do 10408, South Korea
    Recruiting
  • Seoul National University Bundang Hospital
    Seongnam-si, Gyeonggi-do 13620, South Korea
    Recruiting
  • Kyungpook National University Chilgok Hospital
    Daegu, Gyeongsangnam-do 700-721, South Korea
    Recruiting
  • Seoul National University Hospital
    Seoul, 03080, South Korea
    Recruiting
  • Severance Hospital, Yonsei University Health System - Division of Infectious Diseases
    Seoul, 03722, South Korea
    Recruiting
  • Samsung Medical Center
    Seoul, 06351, South Korea
    Recruiting
  • The Catholic University of Korea, Seoul St. Maryâ
    Seoul, 06591, South Korea
    Recruiting
  • Korea University Guro Hospital
    Seoul, 08308, South Korea
    Recruiting
  • Asan Medical Center
    Seoul, 138-736, South Korea
    Recruiting
  • ICO l'Hospitalet - Hospital Duran i Reynals - Servicio de Oncologia
    L'Hospitalet de Llobregat, Barcelona 08906, Spain
    Recruiting

Showing the first 100 of 116 sites across 19 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: Yes — IPD supporting publicly available results will be evaluated for sharing.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report, Analytic code

Time frame: IPD from completed trials will be publicly available within 6 months after all of the following events: Approval of a product/new indication by major authorities (FDA, EMA, PMDA if requested) with no pending submissions Public results via primary manuscript or trial registry disclosure Legal authority to share data Privacy protections are in place If approval is not sought or development is globally discontinued, data will be publicly available within 18 months after global trial completion. Further information on how to request data can be found on our website bit.ly/IPD21

Access criteria: Qualified researchers may propose access to IPD from sponsored trials via https://vivli.org/members/ourmembers/.

Data sharing details ↗ · vivli.org

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2026 (actual). Primary completion is estimated for Oct 2029, 41 months after the start.

Of 69 industry-sponsored phase 3 interventional studies under Colorectal Neoplasms, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 54. This study's planned 41 months is close to that.

Counting every sponsor, half of 175 studies reached it within 50 months; a quarter within 35 and three quarters within 79.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 16, 2026
First posted
Apr 24, 2026
StartActual
May 6, 2026
Primary completionEst.
Oct 16, 2029
CompletionEst.
Oct 16, 2029
Last update
Nov 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
50 sites added — first sites in Italy, Netherlands and Denmark
Show 50 added (9 China, 8 Italy, 6 Spain, 5 France, 4 Taiwan, 3 Germany, 3 Japan, 3 United States, 2 Belgium, 2 Netherlands, 1 Poland, 1 United Kingdom, 1 Austria, 1 Canada, 1 Denmark)
  • UZA - Account 3 · Edegem, Belgium
  • UZ Leuven · Leuven, Belgium
  • Peking Union Medical College Hospital · Beijing, China
  • The University of Hong Kong - 1 · Hong Kong, China
  • Fudan University Shanghai Cancer Center · Shanghai, China
  • Institut Bergonié - Service d'Oncologie Médicale · Bordeaux, France
  • Institut Gustave Roussy - Pathologies Digestives · Villejuif, France
  • Universitaetsklinikum Leipzig AoeR - Universitaeres Krebszentrum Leipzig (UCCL) · Leipzig, Germany
  • Haematologisch-Onkologische Praxis Eppendorf (HOPE) · Hamburg, Germany
  • IEO Istituto Europeo di Oncologia - Divisione Oncologia Medica · San Giovanni Rotondo, Italy
  • Azienda Ospedaliera Universitaria- Università degli Studi della Campania "Luigi Vanvitelli" - Dipartimento di Oncologia · Naples, Italy
  • Istituto Nazionale Tumori Fondazione G. Pascale - Dipartimento Oncoematologia · Naples, Italy
  • Azienda Ospedaliero Universitaria Pisana - U.O. Oncologia II · Pisa, Italy
  • Aichi Cancer Center Hospital · Nagoya, Japan
  • Osaka International Cancer Institute · Osaka, Japan
  • Amphia Ziekenhuis, Molengracht - Parent · Utrecht, Netherlands
  • Wojewodzkie Centrum Onkologii · Gdansk, Poland
  • Hospital Universitario Reina Sofia - Dept of Oncology · Córdoba, Spain
  • Hospital Universitari Vall d'Hebron - Oncology Dept. · Barcelona, Spain
  • Hospital Clinic de Barcelona - Servicio de Oncologia · Barcelona, Spain
  • Hospital Universitario Nuestra Señora de Valme · Seville, Spain
  • Kaohsiung Chang Gung Memorial Hospital · Kaohsiung City, Taiwan
  • National Cheng Kung University Hospital - Internal Medicine · Tainan, Taiwan
  • Chi Mei Hospital, Liouying · Tainan, Taiwan
  • National Taiwan University Hospital · Taipei, Taiwan
  • Sarah Cannon Research Institute UK · London, United Kingdom
  • UCSF Mount Zion Medical Ctr · San Francisco, United States
  • Prisma Health Cancer Institute, ITOR, CRU · Greenville, United States
  • Avera Cancer Institute - 300127370 · Sioux Falls, United States
  • AKH - Medizinische Universität Wien - Klinik für Innere Medizin 1 · Vienna, Austria
  • …and 20 more on the registry record
across 2 updates, Oct 8, 2026 – Nov 5, 2026
Show all 2 updates
  1. Nov 5, 2026
    24 sites added — first site in Denmark
    Show 24 added (6 China, 4 Italy, 3 United States, 3 France, 2 Spain, 1 Austria, 1 Canada, 1 Denmark, 1 Germany, 1 Japan, 1 Netherlands)
    • UCSF Mount Zion Medical Ctr · San Francisco, United States
    • Prisma Health Cancer Institute, ITOR, CRU · Greenville, United States
    • Avera Cancer Institute - 300127370 · Sioux Falls, United States
    • AKH - Medizinische Universität Wien - Klinik für Innere Medizin 1 · Vienna, Austria
    • BC Cancer - Vancouver - BC Cancer Agency · Vancouver, Canada
    • Beijing Cancer Hospital · Beijing, China
    • The Sixth Affiliated Hospital of Sun Yat-sen University · Guangzhou, China
    • Meizhou Peoples Hospital - 300164707 · Meizhou, China
    • The First Affiliated Hospital of Nanchang University - Endocrine Secretion Department · Nanchang, China
    • West China Hospital, Sichuan University · Chengdu, China
    • The First Affiliated Hospital, College of Medicine, Zhejiang University · Hangzhou, China
    • Ålborg Universitets Hospital - PARENT · Herning, Denmark
    • Institut Paoli Calmettes - service d'oncologie medicale · Marseille, France
    • Centre Francois Baclesse - Service d'Oncologie Medicale · Caen, France
    • Hôpital Européen Georges Pompidou - Hématologie Oncologie · Paris, France
    • Charité - Campus Charité Mitte - Medizinische Klinik II (Onkologie u. Haematologie) · Berlin, Germany
    • Azienda Ospedaliera Saverio De Bellis - 300205674 · Castellana Grotte, Italy
    • Azienda Socio Sanitaria Territoriale Niguarda (Grande Ospedale Metropolitano Niguarda) - Struttura Complessa di Oncologia Falck · Milan, Italy
    • IOV - Istituto Oncologico Veneto IRCCS - S.Semplice Dip.Oncologia dei Melanomi · Padova, Italy
    • Fondazione Policlinico Universitario Agostino Gemelli IRCCS - UOC Oncologia Medica · Rome, Italy
    • Shizuoka Cancer Center · Sunto, Japan
    • Universitair Medisch Centrum Groningen - Cancer Center · Groningen, Netherlands
    • ICO l'Hospitalet - Hospital Duran i Reynals - Servicio de Oncologia · L'Hospitalet de Llobregat, Spain
    • Hospital Universitario 12 de Octubre - Servicio de Oncologia · Madrid, Spain
    + 1 other change: verification date
  2. Oct 8, 2026
    26 sites added — first sites in Italy and Netherlands
    Show 26 added (4 Italy, 4 Spain, 4 Taiwan, 3 China, 2 Belgium, 2 France, 2 Germany, 2 Japan, 1 Netherlands, 1 Poland, 1 United Kingdom)
    • UZA - Account 3 · Edegem, Belgium
    • UZ Leuven · Leuven, Belgium
    • Peking Union Medical College Hospital · Beijing, China
    • The University of Hong Kong - 1 · Hong Kong, China
    • Fudan University Shanghai Cancer Center · Shanghai, China
    • Institut Bergonié - Service d'Oncologie Médicale · Bordeaux, France
    • Institut Gustave Roussy - Pathologies Digestives · Villejuif, France
    • Universitaetsklinikum Leipzig AoeR - Universitaeres Krebszentrum Leipzig (UCCL) · Leipzig, Germany
    • Haematologisch-Onkologische Praxis Eppendorf (HOPE) · Hamburg, Germany
    • IEO Istituto Europeo di Oncologia - Divisione Oncologia Medica · San Giovanni Rotondo, Italy
    • Azienda Ospedaliera Universitaria- Università degli Studi della Campania "Luigi Vanvitelli" - Dipartimento di Oncologia · Naples, Italy
    • Istituto Nazionale Tumori Fondazione G. Pascale - Dipartimento Oncoematologia · Naples, Italy
    • Azienda Ospedaliero Universitaria Pisana - U.O. Oncologia II · Pisa, Italy
    • Aichi Cancer Center Hospital · Nagoya, Japan
    • Osaka International Cancer Institute · Osaka, Japan
    • Amphia Ziekenhuis, Molengracht - Parent · Utrecht, Netherlands
    • Wojewodzkie Centrum Onkologii · Gdansk, Poland
    • Hospital Universitario Reina Sofia - Dept of Oncology · Córdoba, Spain
    • Hospital Universitari Vall d'Hebron - Oncology Dept. · Barcelona, Spain
    • Hospital Clinic de Barcelona - Servicio de Oncologia · Barcelona, Spain
    • Hospital Universitario Nuestra Señora de Valme · Seville, Spain
    • Kaohsiung Chang Gung Memorial Hospital · Kaohsiung City, Taiwan
    • National Cheng Kung University Hospital - Internal Medicine · Tainan, Taiwan
    • Chi Mei Hospital, Liouying · Tainan, Taiwan
    • National Taiwan University Hospital · Taipei, Taiwan
    • Sarah Cannon Research Institute UK · London, United Kingdom
    + 2 other changes: verification date and description

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07549412
Responsible party
Sponsor
First posted
Apr 24, 2026
Start date
May 6, 2026
Primary completion
Oct 16, 2029 (estimated)
Completion
Oct 16, 2029 (estimated)
Last update
Nov 5, 2026

Study contacts

US Medical Information
Contact
eMediUSA@emdserono.com
888-275-7376
Communication Center
Contact
service@emdgroup.com
+49 6151 72 5200
Medical Responsible
study director · EMD Serono Research & Development Institute, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Precemtabart tocentecan · Bevacizumab

Start the discussion